Published Date: October 2019
The report " Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Marketed Drug (Esbriet and Ofev), By Mechanism of Action (Antifibrotics, Tyrosine Kinase Inhibitors, Anti-Inflammatory Drugs, Immunosuppressant’s, and Others), By Innovator and Off-Label Drugs (Innovator Drugs and Off-Label Drugs), and Region - Global Forecast to 2029" Global anti-idiopathic pulmonary fibrosis drugs market is projected to grow from US$ XX billion in 2019 to US$ XX billion by 2029. Increasing population across the globe coupled with increasing prevalence of idiopathic pulmonary fibrosis (IPF) are major key drivers of the global anti-idiopathic pulmonary fibrosis drugs market. In addition, key market players are commercializing novel drugs which is another important factor boosting the growth of the target market. Furthermore, hike in cigarette smoking population is expected to propel the growth of the market over the forecast period. Moreover, presence of strong pipeline provided by the government and their policies for the treatment is more likely to increase the growth of global anti-idiopathic pulmonary fibrosis drugs market in the near future. However, there is no specific cure for idiopathic pulmonary fibrosis because of unknown disease etiology, which is the major factor restraining the growth of the target market.
Key Highlights:
- In 2017, according to a comparison study featured in the Journal Pharmacometrics & Systems Pharmacology, first two approved therapies for idiopathic pulmonary fibrosis (IPF) i.e. Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s ofev (nintedanib), were still the most reliable treatments among several approved and experimental therapies.
Key Market Insights from the report:
The global anti-idiopathic pulmonary fibrosis drugs market accounted for US$ XX billion in 2019 and is projected to register a moderate CAGR of XX% over the forecast period. The market report has been segmented on the basis of marketed drug, mechanism of action, innovator and off-label drugs and region.
- By marketed drug, the global anti-idiopathic pulmonary fibrosis drugs market is segmented into esbriet and ofev.
- By mechanism of action, the global anti-idiopathic pulmonary fibrosis drugs market is segmented into antifibrotics, tyrosine kinase inhibitors, anti-inflammatory drugs, immunosuppressant’s, and others
- By innovator and off-label drug, the global anti-idiopathic pulmonary fibrosis drugs market is subdivided into innovator drugs and off-label drugs
- By region, North America dominates the market in terms of revenue due to increased number of pharmaceutical companies and government funding for research and development.
Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on " Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, By Marketed Drug (Esbriet and Ofev), By Mechanism of Action (Antifibrotics, Tyrosine Kinase Inhibitors, Anti-Inflammatory Drugs, Immunosuppressant’s, and Others), By Innovator and Off-Label Drugs (Innovator Drugs and Off-Label Drugs), and by Region (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa)- forecast till 2029
To know the upcoming trends and insights prevalent in this market, click the link below:
The prominent player operating in the global anti-idiopathic pulmonary fibrosis drugs market includes Afferent Pharmaceuticals, Actelion, Asahi Kasei Pharma, Bellerophon Therapeutics, Biogen, Boehringer Ingelheim, FibroGen, Galecto Biotech, Genentech, Global Blood Therapeutics, GSK, and Kadmon Pharmaceuticals
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Custmoized Your ReportWe help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Request for Discount
Quick contact
